GlassScriptPhysician profile
Michele Volansky
NPI 1003944778
$9,375.62
in general payments reported to CMS, 2019-2025
25 companies · $1,750 in 2025
The $1,750 reported for 2025 was more than what 91% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $970 · 2022: $1,641 · 2023: $3,234 · 2024: $1,781 · 2025: $1,750.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,099 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,500 · Education: $165.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,099.36 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,500.00 |
| Education | $164.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,958.82 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,721.39 | 2022-2025 | Saphnelo |
| Amgen INC. | $1,454.12 | 2021-2025 | Enbrel, Otezla, Evenity |
| Genzyme Corporation | $802.92 | 2021-2025 | |
| Janssen Biotech, INC. | $749.05 | 2021-2025 | Tremfya, Simponi Aria, Remicade |
| Ucb, INC. | $675.33 | 2021-2025 | Bimzelx, Cimzia |
| Novartis Pharmaceuticals Corporation | $504.60 | 2021-2025 | |
| Glaxosmithkline, LLC. | $260.83 | 2021-2025 | Benlysta |
| Ani Pharmaceuticals, INC. | $219.64 | 2024 | Purified Cortrophin Gel |
| Radius Health, INC. | $150.44 | 2023-2025 | Tymlos |
| Lilly USA, LLC | $137.80 | 2021-2024 | Taltz |
| Genentech USA, INC. | $123.79 | 2021-2025 | Actemra, Gazyva |
| Sobi, INC | $92.99 | 2021-2025 | |
| Organon LLC | $92.82 | 2023-2025 | Renflexis, Hadlima |
| Pfizer INC. | $84.91 | 2021-2023 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $69.99 | 2021 | |
| Sandoz INC. | $51.87 | 2023-2024 | Hyrimoz |
| E.R. Squibb & Sons, L.L.C. | $44.69 | 2021-2025 | Orencia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.87 | 2023 | Ofev |
| Horizon Therapeutics Plc | $38.10 | 2021-2022 | |
| Aurinia Pharma U.S., INC. | $24.20 | 2025 | Lupkynis |
| Actelion Pharmaceuticals US, INC. | $24.14 | 2022 | |
| Celltrion USA INC. | $19.98 | 2023 | Yuflyma |
| Fresenius Kabi USA, LLC | $17.12 | 2023 | Idacio |
| Ibsa Pharma INC. | $13.21 | 2024 | Licart, Tirosint |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michele Volansky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.